CLAIM AMENDMENTS

1. (Original) A use of a plasminogen activator for manufacturing a medicament for increasing an effect caused by IL-2 inhibitor.

2. (Currently Amended) The ~~use~~ method of ~~the~~ claim ~~1~~ 8, in which the IL-2 inhibitor inhibits the production of IL-2.

3. (Currently Amended) The ~~use~~ method of ~~the~~ claim ~~1~~ 8, in which the IL-2 inhibitor inhibits the activity of IL-2.

4. (Original) The use of the claim 1, in which the effect caused by IL-2 inhibitor is a neuroprotective activity.

5. (Currently Amended) The ~~use~~ method of ~~the~~ claim ~~1~~ 8, in which the IL-2 inhibitor is tacrolimus or its hydrate ~~or cyclosporins~~.

6. (Original) A use of a plasminogen activator and IL-2 inhibitor for manufacturing a medicament for simultaneous, separate or sequential use for neuroprotective activity.

7. (Original) A method for increasing an effect caused by IL-2 inhibitor, by administering a effective amount of a plasminogen activator to a human being or an animal.

8. (Original) A method for preventing or treating acute or chronic cerebral neurodegenerative diseases, by administering a effective amount of a plasminogen activator and an effective amount of IL-2 inhibitor, simultaneously, separately or in sequential use, to a human being or an animal.

9. (Original) A composition comprising a plasminogen activator, for increasing an effect caused by IL-2 inhibitor.

10. (Original) A composition comprising a plasminogen activator and IL-2 inhibitor as a combined preparation for simultaneous, separate or sequential use for neuroprotective activity.

11. (Original) An article of manufacture, comprising packaging material and a plasminogen activator contained within said packaging material, wherein said plasminogen activator is therapeutically effective for increasing an effect caused by IL-2 inhibitor, and wherein said packaging material comprises a label or a written material which indicates that said plasminogen activator can be used for increasing an effect caused by IL-2 inhibitor.

12. (Original) A use of IL-2 inhibitor for manufacturing a medicament for increasing or decreasing an effect caused by plasminogen activator, in which the effect caused by plasminogen activator is a neuroprotective activity or a brain damage appeared in case that plasminogen activator is administered after its proper therapeutic time.

13. (Original) A method for increasing or decreasing an effect caused by plasminogen activator, by administering a effective amount of IL-2 inhibitor, in which the effect caused by plasminogen activator is a neuroprotective activity or a brain damage appeared in case that plasminogen activator is administered after its proper therapeutic time.

14. (Original) A composition comprising IL-2 inhibitor, for increasing or decreasing an effect caused by plasminogen activator.

15. (Original) An article of manufacture, comprising packaging material and IL-2 inhibitor contained within said packaging material, wherein said IL-2 inhibitor is therapeutically effective for increasing or decreasing an effect caused by plasminogen activator, and wherein said packaging material comprises a label or a written material which indicates that said IL-2 inhibitor can be used for increasing or decreasing an effect caused by plasminogen activator.

Please add the following new claims.

16. (New) The method of claim 8, in which the IL-2 inhibitor is cyclosporin A.

17. (New) The method of the claim 8, in which the plasminogen activator is tissue-type plasminogen activator.

18. (New) The method of the claim 8, in which the acute or chronic cerebral neurodegenerative disease is cerebral ischemic disease or brain damage caused by ischemia.

19. (New) The method of the claim 8, in which the acute or chronic cerebral neurodegenerative disease is selected from the group consisting of cerebral infarction, head injury, hemorrhage in brain, cerebral thrombosis, cerebral embolism, cardiac arrest, stroke, transient ischemic attacks (TIA), hypertensive encephalopathy, Alzheimer's disease, Huntington's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS).

20. (New) The method of the claim 8, in which the acute or chronic cerebral neurodegenerative disease is acute stroke.